Literature DB >> 2776821

Sustained-release and instant-release verapamil in treatment of angina pectoris.

C M Jespersen1, N A Klitgaard, H Nielsen, J F Hansen.   

Abstract

The efficacy of a sustained-release preparation of verapamil (verapamil-SR) has been compared with that of a conventional instant-release formulation (verapamil-IR) in 10 patients with stable angina pectoris treated for 3 weeks with both preparations. The diurnal serum concentrations of verapamil and norverapamil did not differ significantly during treatment with verapamil-IR 120 mg t.i.d. and verapamil-SR 360 mg once daily, but verapamil-SR 240 mg produced significantly lower serum concentrations. The differences did not affect the exercise capacity or the occurrence of ST-segment depression during maximal exercise. Verapamil-SR was well tolerated. A multiple instant-release dosage regime can now be replaced by once daily administration of the sustained-release preparation.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2776821     DOI: 10.1007/BF00637748

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  6 in total

1.  An objective evaluation of once-daily sustained-release verapamil (480 mg) in chronic stable angina.

Authors:  E A Rodrigues; P DasGupta; A D Hains; E B Raftery
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

2.  24-hour antiarrhythmic effect of conventional and slow-release verapamil in chronic atrial fibrillation.

Authors:  H Mølgaard; P Bjerregaard; H S Jørgensen; N A Klitgaard
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

3.  Instant and sustained-release verapamil in the treatment of essential hypertension.

Authors:  K Midtbø; O Hals; J van der Meer; L Storstein; O Lauve
Journal:  Am J Cardiol       Date:  1986-02-26       Impact factor: 2.778

4.  Sustained release verapamil, a once daily preparation: objective evaluation using exercise testing, ambulatory monitoring and blood levels in patients with stable angina.

Authors:  R S Kohli; E A Rodrigues; L O Hughes; A Lahiri; E B Raftery
Journal:  J Am Coll Cardiol       Date:  1987-03       Impact factor: 24.094

5.  Pharmacokinetics of conventional and slow-release verapamil.

Authors:  F Follath; H R Ha; E Schütz; F Bühler
Journal:  Br J Clin Pharmacol       Date:  1986       Impact factor: 4.335

Review 6.  Pharmacokinetics of calcium channel blocking agents.

Authors:  P Anderson
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1986
  6 in total
  3 in total

1.  Circadian variation in the pharmacokinetics of verapamil.

Authors:  C M Jespersen; M Frederiksen; J F Hansen; N A Klitgaard; C Sørum
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

Review 2.  Verapamil: a review of its pharmacological properties and therapeutic use in coronary artery disease.

Authors:  R N Brogden; P Benfield
Journal:  Drugs       Date:  1996-05       Impact factor: 9.546

3.  Influence of short term verapamil treatment on glucose metabolism in patients with non-insulin dependent diabetes mellitus.

Authors:  M Busch Sørensen; H Sjøstrand; H Sengeløv; M Tiefenthal Thrane; J Juul Holst; J Lyngsøe
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.